Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Cash flows provided by operating activities:
Net income	$ 1,041	$ 312
Depreciation and amortization	83	91
Amortization of operating lease right-of-use assets	120	116
Stock based compensation	8	15
Change in deferred tax assets	277	(5)
Realized gain on sale of investment in iBio Stock	(56)
Unrealized loss on investment in iBio Stock	29	20
Other, Net	5	9
Changes in operating assets and liabilities:
Accounts receivable	652	1,084
Inventories	(2,655)	(1,073)
Other current assets	(185)
Security deposits and other assets	(26)	18
Accounts payable	2,696	1,251
Accrued expenses and other liabilities	49	(37)
Operating lease obligations	(120)	(116)
Net cash provided by operating activities	1,918	1,685
Cash flows from investing activities:
Purchase of property and equipment	(53)	(58)
Proceeds from sale of iBio Stock	96
Net cash provided by (used in) investing activities	43	(58)
Cash flows from financing activities:
Advances under revolving credit facility	13,921	11,040
Repayments of advances under revolving credit facility	(15,144)	(12,075)
Repayments under term note payables	(734)	(482)
Repayments under finance lease obligations	(37)	(60)
Net cash used in financing activities	(1,994)	(1,577)
Net (decrease) increase in cash	(33)	50
Cash at beginning of period	402	475
Cash at end of period	369	525
Supplemental disclosures of cash flow information:
Interest paid	57	123
Income taxes paid
Supplemental disclosures of non-cash flow transactions:
Amount owed on purchase of property and equipment	$ 20